Retatrutide
Triple GLP-1/GIP/glucagon agonist studied for weight loss and metabolic health.
- How it works
- Triple agonist
- Status
- Phase 3 trials
- How often
- Weekly injection
- Main focus
- Weight management
Dosing
Weeks 1–42 mg weekly
Weeks 5–84 mg weekly
Weeks 9–166–8 mg weekly
Week 17+10–12 mg if tolerated
Results
The source guide reports 24.2% average body-weight loss in Phase 2 and emphasizes slow titration because gastrointestinal effects rise with dose.
Read the results guideBenefits
- Targets GLP-1, GIP, and glucagon
- Strong appetite suppression
- Adds a fat-oxidation pathway
Side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
Educational summary only. Doses shown mirror the linked article, approved labeling, or cited trial schedule; they are not a personal treatment plan.
From Ascension Peptides
View supplierRetatrutide
$175.00
